Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: The role of ΔN-p63

Laboratory Investigation

Volumn 82, Issue 10, 2002, Pages 1335-1345

  Chilosi, Marco ^a,f   Poletti, Venerino ^b,f   Murer, Bruno ^f   Lestani, Maurizio ^a,f   Cancellieri, Alessandra ^c,f   Montagna, Licia ^a,f   Piccoli, Paola ^a,f   Cangi, Giulia ^d,f   Semenzato, Gianpietro ^e,f   Doglioni, Claudio ^e,f  

^a UNIVERSITY OF VERONA   (Italy)

^b Forli Hospital   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e Belluno Hospital   (Italy)

^f Mestre Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA N PROTEIN P63; GENE PRODUCT; ISOPROTEIN; PROTEIN P63; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BASAL CELL; BRONCHIOLE; BRONCHIOLITIS; BRONCHUS MUCOSA; CELL CYCLE; CELL INTERACTION; CELL PROLIFERATION; CELL RENEWAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; EPITHELIUM CELL; EPITHELIZATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS; LUNG FIBROSIS; MALE; MESENCHYME; MODEL; PATHOGENESIS; PRIORITY JOURNAL; TISSUE REPAIR;

AGED; BASE SEQUENCE; BRONCHI; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PROTEIN ISOFORMS; PULMONARY ALVEOLI; PULMONARY FIBROSIS; RESPIRATORY MUCOSA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE DELETION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0036798845     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000032380.82232.67     Document Type: Article

References (51)

1. American Thoracic Society (2000). Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646-664.
2. Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Golden J, Maxwell M, and Selman M (1990). Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 86:1055-1064.
3. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, and Doglioni C (2001). p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25:1054-1060.
4. Boers JE, Ambergen AW, and Thunnissen FB (1998). Number and proliferation of basal and parabasal cells in normal human airway epithelium. Am J Respir Crit Care Med 157:2000-2006.
5. Chilosi M and Doglioni C (2001). Constitutive p63 expression in airway basal cells: A molecular target in diffuse lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 18:23-26.
6. Chilosi M, Lestani M, Benedetti A, Montagna L, Pedron S, Scarpa A, Menestrina F, Hirohashi S, Pizzolo G, and Semenzato G (1993). Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues. Am J Pathol 143:1348-1355.
7. Chilosi M, Piazzola E, Lestani M, Benedetti A, Guasparri I, Granchelli G, Aldovini D, Leonardi E, Pizzolo G, Doglioni C, Menestrina F, and Mariuzzi GM (1998). Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Lab Invest 78:269-276.
8. Crook T, Nicholls JM, Brooks L, O'Nions J, and Allday MJ (2000). High level expression of DN-p63: A mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 19:3439-3444.
9. Dotto GP (2000). p21(WAF1/Cip1): More than a break to the cell cycle? Biochim Biophys Acta 1471:M43-M56.
10. Evans MJ and Moller PC (1991). Biology of airway basal cells. Exp Lung Res 17:513-531.
11. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, and Jacks T (2002). p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560-564.
12. Fukuda Y, Basset F, Ferrans VJ, and Yamanaka N (1995). Significance of early intra-alveolar fibrotic lesions and integrin expression in lung biopsy specimens from patients with idiopathic pulmonary fibrosis. Hum Pathol 26:53-61.
13. Glickman JN, Yang A, Shahsafaei A, McKeon F, and Odze RD (2001). Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 32:1157-1165.
14. Guinee D Jr, Fleming M, Hayashi T, Woodward M, Zhang J, Walls J, Koss M, Ferrans V, and Travis W (1996). Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. Am J Pathol 149:531-538.
15. Hibi K, Nakayama H, Taguchi M, Kasai Y, Ito K, Akiyama S, and Nakao A (2001). AIS overexpression in advanced esophageal cancer. Clin Cancer Res 7:469-472.
16. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, and Sidransky D (2000). AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 97:5462-5467.
17. Hironaka M and Fukayama M (1999). Pulmonary fibrosis and lung carcinoma: A comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol Int 49:1060-1066.
18. Hojo S, Fujita J, Yamadori I, Kamei T, Yoshinouchi T, Ohtsuki Y, Okada H, Bandoh S, Yamaji Y, Takahara J, Fukui T, and Kinoshita M (1998). Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur Respir J 12:1404-1408.
19. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D, Huang X, Sheppard D, and Heller RA (2000). Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA 97:1778-1783.
20. Katzenstein AL and Myers JL (1998). Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification. Am J Respir Crit Care Med 157:1301-1315.
21. Kawasaki H, Nagai K, Yokose T, Yoshida J, Nishimura M, Takahashi K, Suzuki K, Kakinuma R, and Nishiwaki Y (2001). Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 76:53-57.
22. Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, and Strieter RM (2001). ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164:2239-2242.
23. Khalil N, O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, and Greenberg AH (1991). Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 5:155-162.
24. Kolb M, Margetts PJ, Anthony DC, Pitossi F, and Gauldie J (2001). Transient expression of IL-1 beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 107:1529-1536.
25. Kuhn C and Mason RJ (1995). Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 147:1759-1769.
26. Kunitake R, Kuwano K, Miyazaki H, Kawasaki M, Hagimoto N, Fujita M, Kaneko Y, and Hara N (1998). Expression of p53, p21 (Waf1/Cip1/Sdi1) and Fas antigen in collagen vascular and granulomatous lung diseases. Eur Respir J 12:920-925.
27. Kurita T and Cunha GR (2001). Roles of p63 in differentiation of Mullerian duct epithelial cells. Ann NY Acad Sci 948:9-12.
28. Kuwano K, Hagimoto N, Nomoto Y, Kawasaki M, Kunitake R, Fujita M, Miyazaki H, and Hara N (1997). p53 and p21 (Waf1/Cip1) mRNA expression associated with DNA damage and repair in acute immune complex alveolitis in mice. Lab Invest 76:161-169.
29. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N, Nakanishi Y, and Hara N (1996). p21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 154:477-483.
30. Mason RJ, Schwarz MI, Hunninghake GW, and Musson RA (1999). NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis: Past, present, and future. Am J Respir Crit Care Med 160:1771-1777.
31. Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S, and Banba J (1995). Lung cancer associated with usual interstitial pneumonia. Pathol Int 45:925-932.
32. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, and Bradley A (1999). p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708-713.
33. Mizushima Y and Kobayashi M (1995). Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis: A review of Japanese cases. Chest 108:1272-1277.
34. Okudela K, Ito T, Mitsui H, Hayashi H, Udaka N, Kanisawa M, and Kitamura H (1999). The role of p53 in bleomycin-induced DNA damage in the lung: A comparative study with the small intestine. Am J Pathol 155:1341-1351.
35. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, and Ikawa S (1998). Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med 4:839-843.
36. Paakko P, Kaarteenaho-Wiik R, Pollanen R, and Soini Y (2000). Tenascin mRNA expression at the foci of recent injury in usual interstitial pneumonia. Am J Respir Crit Care Med 161:967-972.
37. Parsa R, Yang A, McKeon F, and Green H (1999). Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 113:1099-1105.
38. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, Ponzin D, McKeon F, and De Luca M (2001). p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 98:3156-3161.
39. Poletti V and Kitaichi M (2001). Facts and controversies in the classification of idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis 17:229-238.
40. KIP1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9-22.
41. Quade BJ, Yang A, Wang Y, Sun D, Park J, Sheets EE, Cviko A, Federschneider JM, Peters R, McKeon FD, and Crum CP (2001). Expression of the p53 homologue p63 in early cervical neoplasia. Gynecol Oncol 80:24-29.
42. Ratovitski EA, Patturajan M, Hibi K, Trink B, Yamaguchi K, and Sidransky D (2001). p53 associates with and targets delta Np63 into a protein degradation pathway. Proc Natl Acad Sci USA 98:1817-1822.
43. Selman M, King TE Jr, and Pardo A (2001). Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134:136-151.
44. Sheppard D (2001). Pulmonary fibrosis: A cellular overreaction or a failure of communication? J Clin Invest 107:1501-1502.
45. Turner-Warwick M, Lebowitz M, Burrows B, and Johnson A (1980). Cryptogenic fibrosing alveolitis and lung cancer. Thorax 35:496-499.
46. Uh ST, Inoue Y, King TE Jr, Chan ED, Newman LS, and Riches DW (1998). Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158:1626-1635.
47. Vassilakis DA, Sourvinos G, Spandidos DA, Siafakas NM, and Bouros D (2000). Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 162:1115-1119.
48. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, and McKeon F (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316.
49. Yang A and McKeon F (2000). P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 1:199-207.
50. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, and McKeon F (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714-718.
51. Ziesche R, Hofbauer E, Wittmann K, Petkov V, and Block LH (1999). A preliminary study of long-term treatment with interferon gamma-1β and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341:1264-1269.